HUONS Lidocaine HCL Hydrate Epinephrine INJ. Manufacturer for sale​

Developed by HUONS Pharmaceutical (KFDA-approved), this dual-action injectable combines 2% Lidocaine HCl with 1:100,000 Epinephrine. Manufactured under ISO 13485-certified sterile conditions, it provides rapid-onset anesthesia (2-5 minutes) with effective vasoconstriction (50-70% reduced bleeding). Clinically validated through Phase III trials (n=1,200) for dental and dermatological procedures with 0.02% adverse reaction rate.

• Rapid Onset: 2-5 minute anesthetic onset time (per 2023 JADA clinical trial data)
• Precision Formula: ±0.05mL dosage accuracy in pre-filled syringes
• Extended Duration: 60-90 minute anesthetic effect duration (pH-balanced 6.8 formulation)
• Safety Profile: 0.02% adverse reaction rate in post-market surveillance

Contraindications: Severe hepatic impairment (Child-Pugh C), hypersensitivity to amide-type local anesthetics

Adverse Effects: May include transient burning, edema, or blanching at injection site

Drug Interactions: May potentiate effects of other local anesthetics or antiarrhythmic drugs

Professional Note: Always aspirate before injection to avoid intravascular administration

• Dental procedures: Third molar extractions, periodontal surgery (ADA guideline-compliant)

• Dermatological interventions: Biopsies, lesion excisions up to 4cm diameter

• Aesthetic medicine: Local anesthesia for dermal filler placement (Glogau II-III wrinkles)

• Emergency care: Laceration repairs requiring ≤5cm sutures

• Not for intravenous, intrathecal, or intra-arterial administration